Ivabradine: Indications, Dosing and Heart-Rate Targets

Definition and pharmacological basis

Ivabradine is a selective inhibitor of the If, or “funny,” current in sinoatrial-node pacemaker cells. This current is a mixed inward Na⁺/K⁺ current activated by hyperpolarisation and contributes to spontaneous diastolic depolarisation. By inhibiting the intracellular portion of its transmembrane pore, ivabradine reduces the slope of diastolic depolarisation and produces a dose-dependent reduction in sinus rate.

Its principal therapeutic distinction from beta-blockers is that it lowers heart rate without directly reducing myocardial contractility or altering vascular tone. Accordingly, the source material describes no haemodynamic or contractility effects attributable to ivabradine. Because its action is exerted in the sinus node, it is effective only when the patient is in sinus rhythm. Its role in atrial fibrillation remains uncertain, although it may have a rate-reducing effect in selected circumstances.

Ivabradine undergoes extensive first-pass hepatic metabolism through CYP3A4. Dose adjustment is required in severe hepatic or renal impairment, and clinically relevant interactions occur with CYP3A4 inhibitors and inducers.

Clinical indications

Heart failure with reduced ejection fraction

Ivabradine is an adjunctive option for selected patients with symptomatic HFrEF. The guideline-defined population includes:

• LVEF ≤35%;

• sinus rhythm;

• resting heart rate ≥70 beats/min;

• persistent symptoms despite evidence-based therapy with an ACE inhibitor or ARNI, a beta-blocker and a mineralocorticoid receptor antagonist.

In this setting, ivabradine should be considered to reduce the risk of heart-failure hospitalisation and cardiovascular death. The recommendation is class IIa, level B.

Every effort should be made to initiate and up-titrate beta-blocker therapy to guideline-recommended or maximally tolerated doses before ivabradine is considered. The evidence base included patients with symptomatic NYHA class II or III HFrEF, a previous heart-failure hospitalisation, sinus rhythm and a heart rate above 70 beats/min. The reduction in the combined outcome of cardiovascular death or heart-failure hospitalisation was related to the magnitude of heart-rate reduction.

Ivabradine is also a reasonable consideration when a beta-blocker cannot be tolerated or is contraindicated. In such patients, it may be considered in symptomatic patients with LVEF ≤35%, sinus rhythm and a resting heart rate ≥70 beats/min, provided that treatment includes an ACE inhibitor or ARNI and an MRA. This recommendation is class IIa, level C.

The European regulatory threshold described in the source material differs from the trial-based threshold: ivabradine was approved for patients with HFrEF, LVEF <35%, sinus rhythm and resting heart rate >75 beats/min, based on a retrospective subgroup analysis in which a survival benefit was observed.

Inappropriate sinus tachycardia

Treatment of inappropriate sinus tachycardia begins with assessment and management of reversible causes. Because the prognosis is described as benign, treatment is directed primarily at symptom relief and may not be required in asymptomatic patients.

Before drug treatment, recommended or suggested measures include:

• reassurance;

• exercise training;

• volume expansion;

• avoidance of cardiac stimulants.

Beta-blockers have been used for symptomatic patients, but effective doses may produce troublesome chronic fatigue. Non-dihydropyridine calcium-channel blockers may also be used, although hypotension may limit dosing and evidence for their efficacy is limited.

Ivabradine alone or combined with a beta-blocker should be considered in symptomatic patients. This is a class IIa, level B recommendation. Combination therapy is preferred when feasible because it may provide greater benefit than either drug alone. Long-term efficacy data remain limited, and the possibility that chronic If-channel blockade could increase sympathetic activity, with adverse remodelling or pro-arrhythmic consequences, is noted in the source material.

Other sinus tachycardias

For sinus tachycardia, other medical causes—including myocarditis—should be excluded. Asymptomatic patients may be observed while the heart rate normalises. If symptoms persist or the heart rate remains above 130 beats/min, a beta-blocker is recommended as the principal option; verapamil or ivabradine may be alternatives.

Ivabradine may also be considered in postural orthostatic tachycardia syndrome, although the recommendation is weaker: class IIb, level C. The same guideline table lists regular progressive exercise, increased fluid intake of more than 2–3 L daily and sodium chloride intake of 10–12 g daily as possible measures, with midodrine, a low-dose non-selective beta-blocker or pyridostigmine as additional options.

In sinus-nodal re-entrant tachycardia, the source material supports consideration of verapamil or diltiazem in the absence of HFrEF, and catheter ablation in symptomatic patients who do not respond to drug therapy. It does not establish ivabradine as a principal treatment for this arrhythmia.

Chronic coronary syndrome and stable angina

Ivabradine reduces exercise heart rate and can prolong the time to limiting angina. In patients with stable angina, its exercise effects have been described as comparable to atenolol with respect to exercise performance and the time to ischaemic ST-segment depression.

However, a large study in patients with stable ischaemic heart disease without clinical heart failure and a heart rate ≥70 beats/min did not show a reduction in cardiovascular death or myocardial infarction. A possible adverse effect was observed in the subgroup with activity-limiting angina. Consequently, the source material states that ivabradine has no current role in patients with stable ischaemic heart disease without heart failure.

The chronic coronary syndrome guideline specifically advises against ivabradine as add-on therapy in patients with LVEF >40% and no clinical heart failure. This is a class III, level B recommendation.

In patients with angina and LV dysfunction, ivabradine may be considered in countries where it is available when the heart rate remains above 70 beats/min despite beta-blocker therapy. It is not described as a substitute for the prognostic treatment of LV dysfunction with beta-blockers when those drugs are tolerated.

Heart-rate targets and treatment thresholds

Ivabradine is not prescribed to achieve a universal numerical heart-rate target in all clinical settings. Rather, treatment is considered when residual sinus tachycardia persists despite appropriate management.

The source material does not specify a universally accepted resting heart-rate goal after initiation. Dose reduction is advised if excessive bradycardia develops.

Evaluation before prescribing

Rhythm and electrocardiographic assessment

Since ivabradine acts at the sinus node, documentation of sinus rhythm is essential for the HFrEF indication. It should not be expected to provide the same therapeutic effect in atrial fibrillation or other rhythms in which sinus-node pacing is not the determinant of ventricular rate.

The ECG should also be assessed for:

• sinus bradycardia;

• first-degree atrioventricular block;

• more advanced conduction disease;

• evidence of other rhythm disorders requiring a different management strategy.

Caution is required in patients with sinus bradycardia or first-degree AV block because ivabradine may cause excessive sinus slowing or AV nodal block.

Assessment of the clinical indication

In HFrEF, treatment should follow optimisation of guideline-based therapy. The relevant clinical review includes:

• symptom persistence;

• LVEF;

• current and tolerated beta-blocker dose;

• use of an ACE inhibitor or ARNI;

• use of an MRA;

• resting heart rate;

• cardiac rhythm;

• recent heart-failure hospitalisation where relevant to the evidence base.

In inappropriate sinus tachycardia, reversible causes should be sought and treated before medication is started. The source material does not provide a specific diagnostic algorithm or laboratory panel for this evaluation.

Assessment of comorbidity and drug interactions

Severe hepatic or renal impairment requires dose adjustment. Concomitant medications should be reviewed for CYP3A4 inhibition or induction and for potential QT prolongation.

The source material identifies the following CYP3A4 inhibitors or interacting substances as requiring avoidance or caution:

• ketoconazole;

• verapamil;

• diltiazem;

• clarithromycin;

• grapefruit juice.

Rifampin and carbamazepine are identified as CYP3A4 inducers and should likewise be avoided or used with caution.

Combination with a non-dihydropyridine calcium-channel blocker or another strong CYP3A4 inhibitor is specifically not recommended in chronic coronary syndrome. Combining ivabradine with other QT-prolonging drugs may increase the risk of torsades de pointes.

Dosing and administration

Standard initiation and titration

Ivabradine is typically commenced at:

• 5 mg twice daily.

A lower starting dose is used when the resting heart rate is below 60 beats/min:

• 2.5 mg twice daily.

The dose may be increased to:

• 7.5 mg twice daily,

when a greater heart-rate-lowering effect is required and the drug is tolerated.

Dose titration is typically performed after approximately 2 weeks. If excessive bradycardia occurs, the dose should be reduced.

The source material does not provide a separate dosing schedule for HFrEF, inappropriate sinus tachycardia, postural orthostatic tachycardia syndrome or stable angina. The same practical dose range is therefore the only dosing information specified.

Practical principles of titration

In the absence of an acute indication, therapy should generally begin at a low dose and be increased cautiously according to tolerability and clinical response. This approach reduces dose-related adverse effects but requires reassessment to determine whether sufficient symptom or heart-rate control has been achieved.

The presence of sinus bradycardia, first-degree AV block, severe hepatic or renal impairment, or interacting medication should prompt a particularly cautious approach.

Adverse effects and safety

Cardiovascular effects

Potential cardiac adverse effects include:

• excessive sinus slowing;

• bradycardia;

• AV nodal block;

• possible increased incidence of atrial fibrillation.

Caution is advised in sinus bradycardia and first-degree AV block. The drug should not be combined with non-dihydropyridine calcium-channel blockers or strong CYP3A4 inhibitors in the chronic coronary syndrome setting.

When combined with other drugs that prolong the QT interval, ivabradine may increase the risk of torsades de pointes.

Visual effects

The most common non-cardiac adverse effect identified is a transient visual disturbance, particularly flashes of brightness within the visual field.

Pregnancy and breastfeeding

Ivabradine is contraindicated during pregnancy because of possible fetal toxicity. It should not be taken during pregnancy or breastfeeding.

Drug metabolism and interaction considerations

CYP3A4 metabolism is clinically important. Concomitant CYP3A4 inhibitors can increase exposure, whereas inducers can reduce exposure. The source material specifically lists ketoconazole, verapamil, diltiazem, clarithromycin and grapefruit juice among substances requiring avoidance or caution, and rifampin and carbamazepine among inducers.

Guideline recommendations

HFrEF

Inappropriate sinus tachycardia and related syndromes

Chronic coronary syndrome

The source material also recommends tailoring antianginal therapy to comorbidities, concomitant medications, tolerability and the underlying mechanism of angina. Short-acting nitrates are recommended for immediate relief, while beta-blockers and/or calcium-channel blockers are recommended initially for most patients with chronic coronary syndrome.

Acute and long-term management strategy

Ivabradine is primarily a chronic heart-rate-modifying treatment rather than an acute antiarrhythmic intervention. The source material does not describe an intravenous preparation, an acute loading regimen or a role in emergency termination of tachyarrhythmias.

A practical long-term strategy is therefore:

• Confirm that sinus rhythm is present.

• Identify and correct reversible causes of tachycardia.

• Define the therapeutic context—most importantly symptomatic HFrEF or symptomatic inappropriate sinus tachycardia.

• In HFrEF, optimise ACE inhibitor/ARNI, beta-blocker and MRA treatment before adding ivabradine whenever possible.

• Start at 5 mg twice daily, or 2.5 mg twice daily when the resting heart rate is below 60 beats/min.

• Reassess after approximately 2 weeks.

• Increase to 7.5 mg twice daily only when further effect is needed and bradycardia or conduction disturbance is absent.

• Reduce the dose if excessive sinus slowing develops.

• Review ECG rhythm, heart rate, symptoms, visual disturbances, atrial fibrillation and interacting medication during follow-up.

For inappropriate sinus tachycardia, treatment should remain symptom-oriented because the prognosis is benign and medication may not be necessary. Catheter ablation is not recommended as routine management for most patients because the available evidence is limited and disappointing.

Follow-up and prognosis

Follow-up should assess:

• resting heart rate;

• symptom response;

• sinus rhythm;

• bradycardia or AV block;

• development of atrial fibrillation;

• visual symptoms;

• concomitant QT-prolonging or CYP3A4-interacting drugs;

• hepatic and renal impairment when clinically relevant;

• in HFrEF, persistence of symptoms and adequacy of background guideline-based treatment.

A reassessment approximately 2 weeks after initiation is consistent with the dosing guidance and permits adjustment before longer-term continuation.

In HFrEF, ivabradine is associated with a reduction in the combined risk of cardiovascular death and heart-failure hospitalisation in the selected population described above. The benefit is related to the degree of heart-rate reduction, but the source material does not provide a universal post-treatment heart-rate target.

In inappropriate sinus tachycardia, prognosis is described as benign. Long-term data for ivabradine in this condition are limited, and treatment should therefore be continued according to symptomatic benefit and tolerability rather than an assumption of prognostic improvement.